Checking your sign-in status…

Private workspace

Finance

Research, portfolio tools, and market analysis in one place.

Finance home
Back to US Equities

US Equities · Finance research note

GILD — Gilead Sciences

Research and analysis only
View analysis Browse US Equities

Evidence and analysis

Research evidence pack

Source-backed valuation visuals

Loading verified snapshot
Loading verified market, valuation, and statement data.

2. Company Fundamentals

2.1 Competitiveness

Metric Value
Operating Margins 39.28%
Profit Margins 30.99%
Return on Equity 43.36%
Return on Assets 13.29%
Free Float 1.24B
Dividend Yield 2.65%
Short Int % Utilisation 2.07%

2.2 Growth

Metric Value
Revenue Growth 4.4%
Free Cash Flow 7.93B
EBITDA 11.07 (Ratio)
Enterprise Value 163.1B
EV/Revenue 5.49
EV/EBITDA 11.07

Revenue growth of 4.4% suggests mature or challenged top-line momentum.

2.3 Management

Role Metric
Consensus Rating N/A

2.4 Return

Metric Value
Expected Return (Ann.)* 24.22%
Risk / Std Dev (Ann.)* 26.08%
1-Year Price Return* 19.93%

Latest Market Data (as of 2026-08-14, US Eastern time):

Metric Value
Last Price $138.36
52-Week Range $108.46 – $157.29
Observation Count 251 trading days

The return and risk statistics use daily adjusted closes from the retrieved one-year series and annualise daily moments using 252 trading days. The last price is the latest regular-market price reported for the stated date. Source: Yahoo Finance market data.

DuPont Model Analysis

The DuPont model decomposes return on equity (ROE) into three operating and capital-structure drivers:

ROE = Net Margin × Asset Turnover × Equity Multiplier

The comparison uses the latest two comparable annual periods available for the issuer, with reported statement amounts shown in US$. Revenue and net income are income-statement flows; total assets and shareholders’ equity are year-end balance-sheet figures. This is a simplified year-end-balance DuPont comparison rather than an average-balance ROE calculation.

DuPont component Calculation FY2025 FY2024
Revenue Reported revenue $29.44B $28.75B
Net income Reported net income $8.51B $480.00M
Total assets Year-end reported balance $59.02B $58.99B
Shareholders’ equity Year-end reported balance $22.70B $19.33B
Net margin Net income ÷ revenue 28.90% 1.67%
Asset turnover Revenue ÷ total assets 0.4988x 0.4874x
Equity multiplier Total assets ÷ shareholders’ equity 2.5999x 3.0520x
ROE Net margin × asset turnover × equity multiplier 37.49% 2.48%

Source: Yahoo Finance annual statements. Values are based on the two latest comparable annual periods returned by the source; fiscal period labels use the statement period-end year.

2.5 FCFF DCF Valuation

Valuation basis: This research model follows a five-year, unlevered FCFF DCF. It starts from reported annual operating inputs, forecasts revenue and operating cash conversion under an explicit mechanical policy, discounts FCFF at WACC, applies a Gordon-growth terminal value, and bridges enterprise value to an indicative common-equity value per share. It is an analytical estimate rather than a recommendation or personalised target price.

Step 1 — Forecast Operating Profit and NOPAT

Reported operating input Value
Revenue $29.44B
Prior annual revenue $28.75B
EBIT $10.82B
Tax rate 13.13%
NOPAT = EBIT × (1 − tax rate) $9.40B
Forecast start-growth basis 2.39%
Forecast policy latest reported annual revenue growth, bounded to -10.00% / 15.00%

Step 2 — Calculate FCFF

Current FCFF building block Value
NOPAT $9.40B
Add: depreciation & amortisation $2.76B
Less: capital expenditure -$563.00M
Less/(add): working-capital cash-flow movement -$3.95B
Current unlevered FCFF $7.65B

Explicit FCFF forecast

Forecast year Revenue growth NOPAT D&A Capex Change in NWC FCFF Present value
1 2.39% $9.62B $2.83B -$576.47M -$4.04B $7.83B $7.60B
2 2.42% $9.86B $2.89B -$1.17B -$4.14B $7.45B $6.80B
3 2.45% $10.10B $2.97B -$1.79B -$4.24B $7.04B $6.06B
4 2.47% $10.35B $3.04B -$2.43B -$4.35B $6.61B $5.36B
5 2.50% $10.61B $3.11B -$3.11B -$4.46B $6.15B $4.70B

Step 3 — Determine the Discount Rate (WACC)

WACC input Value
Risk-free rate 4.71%
Equity risk premium assumption 5.50%
Beta 0.34
Cost of equity 6.56%
Pre-tax cost of debt 3.97%
WACC 6.18%
WACC validation requires assumption review

Step 4 — Estimate Terminal Value

Terminal-value input Value
Perpetuity growth rate 2.50%
Terminal value $171.51B
Implied terminal EV / EBITDA 11.19x
Terminal value as % of enterprise value 80.64%

Step 5 — Discount Cash Flows to Enterprise Value

Enterprise-value component Value
Present value of explicit FCFF $30.52B
Present value of terminal value $127.10B
Indicated enterprise value $157.62B
Discounting convention mid-year for explicit FCFF; terminal value discounted at year-end five

Step 6 — Convert Enterprise Value to Equity Value

Equity bridge Value
Indicated enterprise value $157.62B
Less: gross interest-bearing debt $24.94B
Add: cash and equivalents $9.61B
Add: affiliate investments $0.00
Less: minority interests -$84.00M
Indicated common equity value $142.38B

Step 7 — Calculate Indicative Value Per Share

Per-share output Value
Shares used 1,255,000,000.00
Share-count basis reported diluted weighted-average shares
Current market price $143.24
DCF indicative value per share $113.45
Indicative value vs. market price -20.79%

Model Integrity Checks

Check Result
Perpetuity growth is below the risk-free rate pass
Perpetuity growth is below WACC pass
WACC is within the configured operating-company range review required
Terminal-year FCFF is positive pass
Terminal capex converges to D&A pass
Terminal-value concentration within review band
Implied price differs from spot by more than 30% within review band

2.6 Investor-Style Research Screen

Educational screen Result
Buffett-inspired cash-quality checks 4/4 evidenced checks
Lynch-inspired balance-and-growth checks 4/4 evidenced checks

Data lineage: Yahoo Finance public market and reported-statement data; retrieval timestamp: 2026-08-18 17:34:59.263305 UTC; latest reported fiscal period: 2025-12-31 00:00:00. Default assumptions: five-year forecast, mid-year discounting for explicit FCFF, a maximum 2.50% perpetuity-growth rate below both WACC and the risk-free rate, historical operating-ratio persistence, and capex convergence to D&A by year five. No sell-side consensus or management guidance is substituted for reported inputs. This is research and analysis only, not personalized financial advice.

2.7 Quantitative Factor Diagnostics

Model basis: Daily issuer USD excess returns are regressed in-sample using ordinary least squares on matching regional Fama–French factors. FF3 estimates market, size, and value loadings; FF5 adds profitability and investment. Coefficients are descriptive historical exposures, not predictions.

Estimation input Value
Regional factor set US
Factor-return currency USD
Issuer-return basis USD adjusted total return
Estimation window 2025-08-19 to 2026-06-30
Aligned daily observations 217
Minimum observation requirement 120
Currency conversion for HK listings not required

Fama–French Three-Factor and Five-Factor Results

Diagnostic FF3 FF5
Annualised alpha 0.78% 9.22%
Adjusted R² 0.03 0.07
Annualised residual volatility 24.70% 24.03%
Factor loading (t-statistic) FF3 FF5
Market excess return (Mkt-RF) 0.41 (2.83) 0.61 (3.74)
Size (SMB) 0.02 (0.10) -0.15 (-0.71)
Value (HML) 0.14 (0.83) -0.27 (-1.31)
Profitability (RMW) NM 0.11 (0.66)
Investment (CMA) NM 0.95 (3.17)

Definitions: Mkt-RF is the market return less the risk-free rate; SMB is small minus big; HML is high minus low book-to-market; RMW is robust minus weak profitability; CMA is conservative minus aggressive investment. Factor returns are sourced from the Kenneth R. French Data Library; issuer adjusted-return history is sourced from Yahoo Finance. For Hong Kong listings, adjusted HKD prices are converted into USD with daily USD/HKD closes before return calculation to match the USD regional factor basis. This is an in-sample historical regression; coefficients and t-statistics do not establish causation or predict future returns. This is research and analysis only, not personalized financial advice.

us-equitystockequitygildhealth-carebiotechnologynasdaq